Introduction
In natural habitats and in their host environment bacteria most often occur attached to surfaces where they form sessile consortia, or biofilms (3) . Biofilms that develop on indwelling devices (urinary catheters, pacemakers, voice prostheses, contact lenses, etc.) are of major concern in medical practice (2) . The attached mode of growth protects the bacteria from environmental stresses. One serious problem is the much more rapid establishment of antibiotic resistance in biofilm than in plankton (3) .
Escherichia coli is among the predominant species isolated from urinary tract infections. The biofilm-forming strains of uropathogenic E. coli (UPEC) are often a cause of chronic and recurrent infections (4, 14) . UPEC are hard to eradicate by antibiotic therapy, especially in patients with prolonged catheterisation where they develop device-associated biofilms (1, 3, 7, 9, 15) . This necessitates the search of novel approaches to biofilm suppression. One prospective source are substances of plant origin, and this is illustrated for instance by the already popular application of cranberry and blueberry juices in cases of urinary tract infections (6, 10) . The good therapeutic candidates should suppress biofilm growth while not exerting antibacterial activity so that no selective pressure can result in resistance. Ideally, they should also not influence growth and biofilm formation by the non-pathogenic microflora.
Here we report the results of a screening of 14 different extracts from four medicinal plants for antibacterial and antibiofilm activity against three clinical isolates of E. colitwo from urinary-tract infection and one from asymptomatic bacteriuria.
Materials and Methods

Strains, media and cultivation
In this study were included three urinary clinically isolated strains with pre-estimated good biofilm growth capacity (11) from the laboratory collection of the Departnemt of Biochemistry and Microbiology, Plovdiv University. PU-1 was isolated from a woman with pyelonephritis, PU-13 -from a man with cystitis, and PU-19 -from a man with ABU. Estimation of the antibacterial activity of the plant extracts was tested also on reference strains: E. coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 25923 and Streptococcus saprophyticus nctc 7292.
The strains were stored frozen in Trypticase soy broth (TSB) (Difco) supplemented with 30% glycerol. Before use, samples were inoculated into TSB and incubated overnight at 37 °C. Then bacteria were streaked on nutrient agar for single colony separation. Three single colonies were selected, applied separately to slant trypticase soy agar, incubated overnight at 37 °C and kept refrigerated until use but no longer than 30 days. Samples from these were examined in parallel in the biofilm experiments.
EffEctS of ExtractS froM MEdIcInal plantS on bIofIlM forMatIon by escherichia coli urInary tract ISolatES
plant extracts
Fourteen different extracts from four medicinal plants were included in the study. Extraction of Rhodiola rosea with acetone, Arnica montana with chloroform and, Petasites albus, Petasites hybridus with methanol gave total extracts (Rr 1, Am 1, Pa 1, and Ph 1), respectively. F1, F2, and F3 were obtained by separation of Rr1 on Sephadex LH-20 column using EtOH for elution. Am1 was prepared by precipitation with Pb(OAc) 2 , filtration and extraction of the filtrate with CHCl 3 . Extracts Pa 2 -Pa 4 and Ph 2 -Ph 4 were prepared from Pa 1 and Ph 1, respectively. The methanol extracts were dissolved in 50% aqueous methanol, and successively extracted with hexane, chlorophorm and butanol. The plants, mode of extraction and chemical composition are given in table 1. The extracts were suspended as stocks in ethanol to concentrations of 10 mg/ml and stored frozen until use.
disk diffusion assay
The classical disk-diffusion assay was applied first to characterize the antibiotic resistance of the urinary strains. This was performed with discs (Bioanalyse-Ankara, Turkey) soaked with the following antibiotics: ampicillin, ampicillin/ sulbactam, cefuroxime, cefotaxime, cefotaxime/clavulanic acid, nitrofurantoin, gentamycin, amikacin, nalidixic acid, ciprofloxacin, and trimethophorin/sulfamethoxazole. The disks were applied on Müller-Hinton agar plates (NCIPD, Sofia, Bulgaria). The test was also applied to examine the antibacterial activities of the plant extracts. Initially, discs loaded with 50 μg of the extracts were tested against the set of two Gram-negative and two Gram-positive strains referent for antibiotic activities. In a separate series of experiments, disks were loaded with increasing amounts from each extract: 5, 10, 50, 100, and 200 μg, air dried and applied on the Müller-Hinton agar plated with the tested E. coli clinical isolates. 
20 ºC. Planktonic cells were removed, the wells were washed 3 times in 0.85% NaCl and the biofilms were stained with 0.1% crystal violet for 10 min. The dye was solubilised with 150 μl 75% ethanol per well and the absorbance was measured on a plate reader at 550 nm. Each variant was applied on 6 wells per sample and repeated with bacteria originating from 3 separate colonies from each strain. The data were processed by variation statistics using the Student-Fisher test.
Effects of the extracts on bacterial growth
To check for the effects of the plant extracts on the bacterial growth course under the nutrient limitation applied in the biofilm trials, plates with 100 μl of M63 -pure or supplemented as above, were cultivated at 37 °C and absorbance was measured hourly at 620 nm wavelength until the stationary phase was reached.
results and discussion
We first characterised the antibacterial activities of the plant extracts on a set of Gram-positive and Gram-negative reference strains. The disk diffusion assay showed that the substances were either inactive, or with low activity against the Gram-positive strains only. Bacteriostatic or weak bactericidal activity (inhibition zones c.a. 8-12 mm) against S. aureus and S. saprophyticus was recorded upon application of 50 μg of Rr4, Pa1, Pa2 and Ph4. As a second task, we applied the disk-diffusion assay to characterise the clinical E. coli strains included in the study with regard to their antibiotic sensitivity. The two UPEC strains can be characterised as susceptible to most of the standardly applied antibiotics: PU-1 was inhibited only by ampicillin and ampicillin/sulbactam, and PU-13, by ampicillin and trimethoprim/sulfomethoxazole. Contrary to this, the ABU strain PU-19 was multiresistant and inhibition zones were registered only around disks loaded with cefotaxime/clavulanic acid, nitrofurantoin, and amikacin. Unrelated with the antibiotic-resistance profiles, the diskdiffusion assay characterised the three strains as generally not sensitive to the plant extracts, the only exception being the formation of little inhibition zones around the disks loaded with 50, 100 and 200 μg of Pa2 and applied to PU-19.
Contrary to the lack of effects of the above amounts of the extracts, the addition of only 10 μg/ml during biofilm growth, resulted in a variety of biofilm modulation activities (table 2). Biofilm growth of the UPEC strain PU-1 was generally suppressed by all the supplements, whereas with strain PU-13 the effects ranged from suppression through no statistically significant effect to stimulation. Notably, most of the extracts stimulated biofilm growth in the ABU strain.
The extracts Rr1, Rr2, Am1 and Am2 were biofilminhibitory to both UPEC strains, hence promising for practical applications, and were subjected to further analysis. Contrary to UPEC, the four extracts stimulated biofilm growth in the ABU strain PU-19 (Fig. 1) . This stimulation was the highest with Rr1 where biofilm growth was almost fourfold that of the control.
The extracts had no effect on the plankton growth course in M63 medium of PU-1 and PU-13. However, opposite to biofilm stimulation the four extracts affected the growth of PU-19 (Fig. 2) . With Rr1, the extract that had the highest biofilmstimulation effect on this strain, the stationary phase of growth tablE 2 Effects (% of control ± standard deviation) of plant extracts on biofilm growth by UPEC clinical isolates pu-1 pu-13 pu-19 control 100 100 100 was recorded at a lower turbidity value than in the control. For the other three extracts, slowing down of bacterial growth was noted in the beginning but the stationary phase was registered at turbidity similar to that of the control. The chosen plant species are known for their use in nontraditional medicine. The results from the present experiments showed however little potential for antibacterial applications. This was shown with the standard reference strain panel of four Gram-positive and Gram-negative bacteria, where low bacteriostatic or bactericidal effects of Rr4, Pa1, Pa2 and Ph4 were recoded on the Gram-negative strains only. The lack of activity was confirmed for the E. coli clinical isolates included in the study. This is opposed by the wide range of biofilm modulating activities of the plant preparations. The effects varied and were E. coli strain-specific. Four of the extracts, Rr1, Rr2, Am1 and Am2 were biofilm suppressing against both UPEC strains, and may be a source of potentially useful substances for medicinal applications. What is more, these substances stimulated instead of suppressing sessile growth in the ABU strain. It is tempting to relate this to antibiotic susceptibility, especially of the multidrug resistance strain E. coli pu-19.
Since biofilm growth can be accepted as a way of bacteria to overcome unfavourable environmental conditions (8) , this strain could be considered as a better survivor than the other two. This suggestion is however not the likely explanation of the results, and is contradicted by the observed suppression effects of Rr1, Rr2, Am1 and Am2 on the growth course of PU-19 in M63 medium. Likely results were earlier observed with spent cultures of several probiotic bacterial species that had antibacterial activity against enteroaggregative E. coli, but stimulated instead of suppressing biofilm growth (12) . Such results could be explained by switching on of hitherto unknown protective mechanisms in E. coli.
Last but not least is the observation of the opposite effects of Rr1, Rr2, Am1 and Am2 on the strains: suppressing the biofilm growth in the UPEC and stimulating it in the ABU. Most of the present-day biofilm research on urinary clinical E. coli isolates was concentrated on UPEC strains. ABU strains for which less is known can reside in the urinary tract without causing pathology. Recently, it has been established that ABU strains may be better biofilm formers than UPEC, and can outcompete them in the colonisation of surfaces (5, 13) . The here registered opposite effects on pathogenic and -1 (a, b, c, d ), E. coli PU -13 (E, f, G, H) , and E. coli pu-19 (I, J, K, l) by the extracts Rr1 (a, E, I), Rr2 (b, f, J), Am1 (c, G, K) and Am2 (d, H, l) non-pathogenic strains by Rr1, Rr2, Am1 and Am2 confirm that they have good potential for antibiofilm applications in medical practice. Further studies are needed to identify the active biofilm-modulating substances.
conclusions
Fourteen samples from four medicinal plants in different organic solvents were examined for antibacterial and antibiofilm activities. The samples generally lacked antibacterial activity but were characterised by a wide range of biofilm modulating activities. Four of the extracts suppressed biofilm growth in UPEC strains but stimulated it significantly in the ABU strain. Such effect is in accordance with the novel demands for biofilm suppression of pathogens without antibacterial activity so that resistance development can be avoided. The eventual selectivity of the preparations against sessile growth of pathogenic strains only and the nature of the active substances need further examination.
